benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate | 348626-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate
• 英文别名: benzyl 4-(2-oxo-1-pyrrolidinyl)phenyl-carbamate；benzyl 4-(2-oxo-1-pyrrolidinyl)phenylcarbamate；benzyl N-[4-(2-oxopyrrolidin-1-yl)phenyl]carbamate
• CAS: 348626-48-2
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: KHKPKIOFQNTCEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate 在 正丁基锂 、 异戊醇 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 7.42h， 生成 (5S)-5-(aminomethyl)-3-[4-(2-oxopyrrolidin-1-yl)phenyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939):  An Oral, Direct Factor Xa Inhibitor

  摘要：

  Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-molecule inhibitors with good oral bioavailability. We identified oxazolidinone derivatives as a new class of potent FXa inhibitors. Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity. The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity. The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.

  DOI：

  10.1021/jm050101d
• 作为产物：
  描述：

  1-(4-氨基苯基)-2-吡咯烷酮 、 氯甲酸苄酯 在 magnesium sulfate 作用下， 以 四氢呋喃 、 乙酸乙酯 、 N,N-二甲基苯胺 为溶剂， 生成 benzyl [4-(2-oxopyrrolidin-1-yl)phenyl]carbamate
  参考文献：
  名称：

  MICROANGIOPATHY TREATMENT AND PREVENTION

  摘要：

  本发明涉及选择性因子Xa抑制剂的使用，特别是公式(I)的噁唑烷酮，用于治疗和/或预防微血管病，并且它们用于生产用于治疗和/或预防微血管病的药物。

  公开号：

  US20100160301A1

文献信息

• COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES
  申请人：Perzborn Elisabeth

  公开号：US20100120718A1

  公开（公告）日：2010-05-13

  The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P 2 Y 12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.

  本发明涉及A) 公式（I）的噁唑烷二酮与B) 乙酰水杨酸（阿司匹林）和C) ADP受体拮抗剂的组合物，特别是P2Y12嘌呤受体阻滞剂，以及制备这些组合物的方法和将其用作药物，特别是用于预防和/或治疗血栓栓塞性疾病。
• Substituted oxazolidinones and their in the field of blood coagulation
  申请人：——

  公开号：US20030153610A1

  公开（公告）日：2003-08-14

  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) 1 processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

  这项发明涉及血液凝固领域。描述了一种新颖的一舁氧杂环丙烷衍生物，其一舁通式为（I）的制备方法以及它们作为药用活性化合物用于预防和/或治疗疾病的用途。
• Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders
  申请人：Perzborn Elisabeth

  公开号：US20080306070A1

  公开（公告）日：2008-12-11

  The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

  本发明涉及A) 具有化学式(I)的噁唑烷二酮与B) 抗心律失常药物的组合物，以及用于制备这些组合物的方法，它们用于预防和/或治疗疾病，并且用于制造用于预防和/或治疗疾病，特别是血栓栓塞性疾病和/或并发症的药物。
• Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation
  申请人：Straub Alexander

  公开号：US20060258724A1

  公开（公告）日：2006-11-16

  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

  本发明涉及血凝领域。描述了一种新的氧唑啉衍生物，其通式为（I），以及它们的制备方法和用作药物活性化合物用于预防和/或治疗疾病的应用。
• SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION
  申请人：Straub Alexander

  公开号：US20080090815A1

  公开（公告）日：2008-04-17

  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

  该发明涉及血凝领域。描述了一种新的氧杂环己酮衍生物的一般式（I），以及它们的制备方法和作为药物活性化合物用于预防和/或治疗疾病的用途。